Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
7.69
-0.16 (-2.04%)
At close: Jan 30, 2026, 4:00 PM EST
7.71
+0.02 (0.27%)
After-hours: Jan 30, 2026, 7:59 PM EST
Ardelyx Revenue
Ardelyx had revenue of $110.33M in the quarter ending September 30, 2025, with 12.30% growth. This brings the company's revenue in the last twelve months to $398.23M, up 58.12% year-over-year. In the year 2024, Ardelyx had annual revenue of $333.62M with 168.06% growth.
Revenue (ttm)
$398.23M
Revenue Growth
+58.12%
P/S Ratio
4.62
Revenue / Employee
$1,008,187
Employees
395
Market Cap
1.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 333.62M | 209.16M | 168.06% |
| Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
| Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
| Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
| Dec 31, 2020 | 7.57M | 2.29M | 43.36% |
| Dec 31, 2019 | 5.28M | 2.67M | 102.57% |
| Dec 31, 2018 | 2.61M | -39.39M | -93.79% |
| Dec 31, 2017 | 42.00M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 24.03M | -7.60M | -24.02% |
| Dec 31, 2014 | 31.62M | 2.70M | 9.32% |
| Dec 31, 2013 | 28.93M | 23.52M | 434.71% |
| Dec 31, 2012 | 5.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zai Lab | 441.63M |
| MannKind | 313.79M |
| Aurinia Pharmaceuticals | 265.81M |
| Vericel | 258.72M |
| Stoke Therapeutics | 205.63M |
| Syndax Pharmaceuticals | 111.30M |
| Ocular Therapeutix | 55.78M |
| Nuvation Bio | 26.75M |
ARDX News
- 3 days ago - First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA - GlobeNewsWire
- 10 days ago - Ardelyx: Assessment Of Acquisition Rumors - Seeking Alpha
- 11 days ago - Ardelyx: IBSRELA Momentum Drives Opportunity - Seeking Alpha
- 23 days ago - Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook - GlobeNewsWire
- 3 months ago - Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week - GlobeNewsWire
- 3 months ago - Ardelyx to Participate at the Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 3 months ago - Ardelyx: Impressive Q3 Record Growth - Why I Buy - Seeking Alpha
- 3 months ago - Ardelyx: A Long Overdue Rally - Seeking Alpha